FLI-06
Based on 10 publication(s) in Google Scholar
FLI-06 is an inhibitor of Notch signaling with an EC50 of 2.3 μM.
For research use only. We do not sell to patients.
- Purity: 99.88%
- CAS No.: 313967-18-9
- Formula: C25H30N2O5
- Molecular Weight:438.52
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Neuronal Signaling Compound Library
HY-L013
-
Stem Cell Signaling Compound Library
HY-L017
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Differentiation Inducing Compound Library
HY-L038
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Cancer Stem Cells Compound Library
HY-L135
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
Publications Citing Use of MedChemExpress (MCE) FLI-06
More- Immunity. 2024 Apr 11:S1074-7613(24)00141-9. [Abstract]
- Pharmacol Res. 2019 Oct:148:104406. [Abstract]
- Cell Death Dis. 2020 Nov 15;11(11):981. [Abstract]
- EMBO J. 2024 Oct;43(20):4625-4655. [Abstract]
- Biomed Pharmacother. 2018 Nov:107:1370-1376. [Abstract]
- Int J Mol Med. 2018 Aug;42(2):1008-1017. [Abstract]
- Fundam Clin Pharmacol. 2021 Aug;35(4):690-699. [Abstract]
- Int J Rheum Dis. 2021 Jul;24(7):922-929. [Abstract]
- J Int Med Res. 2020 Sep;48(9):300060520943790. [Abstract]
- Harvard University. 2025.
Customer Validation & Images
-
WB
-
WB
Biological Activity
EC50: 2.3 μM (Notch signaling)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
1.8 μM
Compound: 1; FLI-06
|
Antiproliferative activity against human HCT116 cells after 72 hrs by SYBR green dye based fluorescence assay
Antiproliferative activity against human HCT116 cells after 72 hrs by SYBR green dye based fluorescence assay
|
[PMID: 30201292] |
| HeLa | IC50 |
2.3 μM
Compound: 6; FLI-06
|
Inhibition of gamma secretase mediated Notch delta E activation in human HeLa cells expressing EGFP after 16 hrs by immunofluorescence analysis
Inhibition of gamma secretase mediated Notch delta E activation in human HeLa cells expressing EGFP after 16 hrs by immunofluorescence analysis
|
[PMID: 27045975] |
| MDA-MB-231 | IC50 |
4 μM
Compound: Figure3,5
|
Cytotoxicity against human MDA-MB-231 cells
Cytotoxicity against human MDA-MB-231 cells
|
[PMID: 26115571] |
FLI-06, disrupted the Golgi apparatus in a manner distinct from that of brefeldin A and golgicide A. FLI-06 inhibited general secretion at a step before exit from the endoplasmic reticulum. In FLI-06–treated cells, no APPCTF accumulates despite strongly reduced Aβ secretion, suggesting that it acts upstream of α-secretase and β-secretase cleavage. FLI-06 is a very useful chemical probe to study the inhibition of membrane traffic at pre- ER-exit site (ERES) stages without fusion of ER-Golgi[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 313967-18-9
-
Appearance Solid
-
Molecular Weight 438.52
-
Formula C25H30N2O5
-
Color Light yellow to yellow
-
SMILES
O=C(C1=C(C)NC2=C(C(CC(C)(C)C2)=O)C1C3=CC=C([N+]([O-])=O)C=C3)OC4CCCCC4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Immunity
Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages. [Abstract]2024 Apr 11:S1074-7613(24)00141-9. PMID: 38636522 -
Pharmacol Res
Novel ADAM-17 inhibitor ZLDI-8 inhibits the proliferation and metastasis of chemo-resistant non-small-cell lung cancer by reversing Notch and epithelial mesenchymal transition in vitro and in vivo. [Abstract]2019 Oct:148:104406. PMID: 31442576 -
Cell Death Dis
ZEB1-activated LINC01123 accelerates the malignancy in lung adenocarcinoma through NOTCH signaling pathway. [Abstract]2020 Nov 15;11(11):981. PMID: 33191397 -
EMBO J
Interaction of chikungunya virus glycoproteins with macrophage factors controls virion production. [Abstract]2024 Oct;43(20):4625-4655. PMID: 39261662 -
Biomed Pharmacother
FLI-06 suppresses proliferation, induces apoptosis and cell cycle arrest by targeting LSD1 and Notch pathway in esophageal squamous cell carcinoma cells. [Abstract]2018 Nov:107:1370-1376. PMID: 30257352
FLI-06 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Nov:107:1370-1376. [Abstract]
ECa109 and EC9706 cells are treated with different concentrations of FLI-06 (0, 10 and 20 μM) for 48 h, respectively. The expressions of Notch3, DTX1 and Hes1 are investigated by Western blotting.
FLI-06 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Nov:107:1370-1376. [Abstract]
ECa109 and EC9706 cells are treated with different concentrations of FLI-06 (0, 10 and 20 μM) for 48 h, respectively. The expressions of LSD1 and H3K4me2 are investigated by Western blotting.
-
Int J Mol Med
2018 Aug;42(2):1008-1017. PMID: 29750292 -
Fundam Clin Pharmacol
Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma. [Abstract]2021 Aug;35(4):690-699. PMID: 33015852 -
Int J Rheum Dis
Survivin promotes rheumatoid arthritis fibroblast-like synoviocyte cell proliferation, and the expression of angiogenesis-related proteins by activating the NOTCH pathway. [Abstract]2021 Jul;24(7):922-929. PMID: 34096679 -
J Int Med Res
2020 Sep;48(9):300060520943790. PMID: 32967512 -
Solvent & Solubility
DMSO : ≥ 38 mg/mL (86.66 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.70 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.70 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
EC50 values of the test compounds are calculated from serial dilution series ranging from 200 to 0.1 μM. Cells are seeded in 96-well plates at a density of 5,000 cells per well in 100 μL medium. The next day, 100 μL medium containing each test compound is added. Cells are incubated for 16 h, fixed and processed for automated microscopy. EC50 estimates are calculated using four-parameter log-logistic fit with the package drc[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2804 mL | 11.4020 mL | 22.8040 mL | 57.0099 mL |
| 5 mM | 0.4561 mL | 2.2804 mL | 4.5608 mL | 11.4020 mL | |
| 10 mM | 0.2280 mL | 1.1402 mL | 2.2804 mL | 5.7010 mL | |
| 15 mM | 0.1520 mL | 0.7601 mL | 1.5203 mL | 3.8007 mL | |
| 20 mM | 0.1140 mL | 0.5701 mL | 1.1402 mL | 2.8505 mL | |
| 25 mM | 0.0912 mL | 0.4561 mL | 0.9122 mL | 2.2804 mL | |
| 30 mM | 0.0760 mL | 0.3801 mL | 0.7601 mL | 1.9003 mL | |
| 40 mM | 0.0570 mL | 0.2850 mL | 0.5701 mL | 1.4252 mL | |
| 50 mM | 0.0456 mL | 0.2280 mL | 0.4561 mL | 1.1402 mL | |
| 60 mM | 0.0380 mL | 0.1900 mL | 0.3801 mL | 0.9502 mL | |
| 80 mM | 0.0285 mL | 0.1425 mL | 0.2850 mL | 0.7126 mL |
Powered by Bioz